Psylo Pty Ltd
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Psylo Pty Ltd - overview
Established
2021
Location
Sydney, NSW, Australia
Primary Industry
Biotechnology
About
Based in Sydney, Australia, and founded in 2021, Psylo focuses on the development of psychedelic-inspired medicine to treat mental illness, with an initial USD 1. 1 million in the capital. The Chief Scientific Officer, Samuel Banister, is formerly the team leader in medicinal chemistry at the Brain and Mind Centre at the University of Sydney. The company focuses on psychedelic-assisted therapy using psilocybin, which is being evaluated as a potential treatment for severe mental illness.
It is developing a shorter-acting version of psilocybin, which normally takes effect for 6-8 hours in duration.
Current Investors
Main Sequence Ventures, Lionheart Ventures, Negev Capital
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Pharmaceuticals
Website
www.psylo.bio
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.